Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH |
December 03, 2018 | December 2018 Bond Updates |
OSLO, Dec. 3, 2018 /PRNewswire/ -- Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL) Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and... |
View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-single-administration-betalutin-r-is-effective-and-well-tolerated-in-r-r-inhl-patients-6-month-follow-up-data-presented-at-ash-841004804.html |
Related News |